Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
cancer
cancer immunotherapy
center for medicare and medicaid services
companion diagnostic
daniel o'day
1
×
deals
1
×
fda
foundation medicine
foundationone cdx
foundationone heme
genentech
life sciences
national blog main
national top stories
new york blog main
osimertinib
1
×
roche
rucaparib (rubraca)
san francisco blog main
What
acquire
agreed
big
billion
broad
confidence
didn’t
foundation
gain
genentech
medicine
1
×
momentum
morning
panels
pay
pays
picked
profiling
recently
redux
remaining
rest
roche
share
stock
1
×
struggled
traction
tumor
vote
Language
Current search:
stock
×
deals
×
" daniel o'day "
×
osimertinib
×
medicine
×
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine